This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).
Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.
This trial was terminated before completion. Termination can indicate safety signals, futility findings, or business/regulatory decisions by the sponsor.
Fulcrum Therapeutics (FULC) is the sponsoring company for this trial. BiotechSign currently grades this company F (17/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.